Sugi Predict

Sugi Predict / Compounds / SCHEMBL7180850

SCHEMBL7180850

SCHEMBL7180850

Cc1cc(C(C)(C)C)cc(C)c1C(=O)C(CCCP=O)c1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.34
▸ CYP3A4 P08684 2/20 0.34
▸ CYP2C9 P11712 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ CCR2 P41597 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ EPHX1 P07099 5/20 0.33
▸ CNR1 P21554 1/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ TACR1 P25103 1/20 0.32
▸ RXRB P28702 2/20 0.32
▸ RXRA P19793 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ KDM4A O75164 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7184980 0.96 CYP2C19 (0.34) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL7179809 0.93 CYP1A2 (0.36) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL7182688 0.89 SLC6A2 (0.35) LMNAHSD17B10MEN1ALDH1A1KMT2A
SCHEMBL7180897 0.86 L3MBTL1 (0.39) CYP1A2CYP3A4CYP2C9CYP2C19LMNA
SCHEMBL7188866 0.85 ALDH1A1 (0.34) CYP2C19LMNAHSD17B10MEN1ALDH1A1
SCHEMBL7183772 0.85 CYP1A2 (0.37) CYP1A2CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL7175023 0.84 LMNA (0.35) CCR2LMNAHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL7177336 0.82 L3MBTL1 (0.38) CYP1A2CYP3A4CYP2C9CYP2C19LMNA
SCHEMBL7182287 0.81 SLC6A2 (0.36) LMNAHSD17B10MEN1ALDH1A1KMT2A
SCHEMBL7176015 0.81 LMNA (0.35) CYP2C19LMNAHSD17B10ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 CYP1A2 1595/4885CYP3A4 1652/4885CYP2C9 1094/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 CYP1A2 2020/4885CYP3A4 1881/4885CYP2C9 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.